Jason Coloma, Ph.D.
Jason joined Third Rock in 2017 to focus on new company formation and business development across our portfolio. His portfolio company roles include:
- Interim chief business officer of Celsius Therapeutics
Jason is an experienced biopharma executive and brings significant corporate development expertise to the role. Prior to joining Third Rock, Jason was the senior vice president and chief business officer at Corvus Pharmaceuticals where he was responsible for corporate development, investor relations, and corporate communications. At Corvus, Jason established several partnerships with academic investigators and industry collaborators. From 2008-2016 he held a number of roles at Roche, including vice president & global therapeutic area head of oncology and cancer immunotherapy partnering. He was also the global head of innovation partnering where he was responsible for early drug discovery stage partnerships across all therapeutic areas. At Roche, Jason led or oversaw numerous transactions ranging from research collaborations to mergers and acquisitions (M&A) including partnerships with Third Rock portfolio companies Foundation Medicine and Blueprint Medicines. Before joining Roche, Jason was a consultant in the life sciences practice at L.E.K. Consulting, where he focused on business development and corporate strategy for biopharma clients. He also worked in finance at Amgen and in research at the University of California, San Francisco and Cytokinetics. Jason completed his Ph.D. and M.P.H. at the University of California, Berkeley, his MBA from the Tuck School of Business at Dartmouth, and a B.S. in Biology at the University of San Francisco.
Although Jason has spent nearly a decade living outside the United States, he is embarrassed to admit that his language skills are limited to asking for the check and the bathroom in German, French, Italian, and Japanese.